2014

Barthel C, Biedermann L, Frei P, Vavricka SR, Kündig T, Fried M, Rogler G, Scharl M. Induction or Exacerbation of Psoriasis in Patients with Crohn’s Disease under Treatment with Anti-TNF Antibodies. Digestion 2014;89:209–215 DOI: 10.1159/000358288 IF = 3.361 [Abstract]

Maillard MH, Bortolotti M, Vader J-P, Mottet C, Schoepfer A, Gonvers J-J, Burnand B, Froehlich F, Michetti P, Pittet V, The Swiss IBD Cohort Study Group. Appropriateness and long-term discontinuation rate of biological therapies in ulcerative colitis. J. Crohns colitis, 2014 Jan 21. pii: S1873-9946(14)00004-X.  PMID:24462322 (PubMed - as supplied by publisher) Aug 2013. IF = 3.385 [Abstract

Mecklenburg I, Reznik D, Fasler-Kan E, Drewe J, Beglinger C, Hruz P, On behalf of the Swiss IBD Cohort Study Group. Serum hepcidin concentrations correlate with ferritin in patients with inflammatory  bowel disease Mecklenburg l, et al, Serum hepcidin concentrations correlate with ferritin in patients with inflammatory bowel disease. J Crohns Colitis (2014)J Crohns Colitis. 2014 May 10. pii: S1873-9946(14)00153-6. doi: 10.1016/j.crohns.2014.04.008. IF = 3.385 [Abstract]

Pittet V, Rogler G, Mottet C, Froehlich F, Michetti P, de Saussure P, Burnand B, Vader JP & the Swiss Ibd cohort study group. Patient's information-seeking activity is associated with treatment compliance in inflammatory  bowel disease patients. Scandinavian Journal of Gastroenterology. 2014; Early online, 1-12. IF = 2.156 [Abstract]

Schaffer T, Schoepfer AM, Seibold F, on behalf of the Swiss IBD Cohort Study Group. Serum ficolin-2 correlates worse than fecal calprotectin and CRP with endoscopic Crohn's disease activity. Schaffer T, et al, Serum ficolin-2 correlates worse than fecal calprotectin and CRP with endoscopic Crohn's disease activity, J Crohns Colitis (2014). IF = 3.385 [Abstract]

Vavricka SR, Schoepfer AM, Scharl M, Rogler G. Steroid Use in Crohn's Disease. Drugs. 2014 Mar;74(3):313-24. doi: 10.1007/s40265-014-0183-y. IF = 4.633 [Abstract]

 

2013

Becker HM, Bertschinger MM, Rogler G. Microparticles and their impact on intestinal immunity. Dig Dis. 2012; 30 Suppl 3:47-54. doi: 10.1159/000342602. Epub 2013 Jan 3. IF = 2.373 [Abstract]

Biedermann L, Rogler G. Environmental factors and their impact on the intestinal microbiota: a role for human disease? Dig Dis. 2012;30 Suppl 3:20-7. doi: 10.1159/000342590. Epub 2013 Jan 3. IF = 2.373 [Abstract]

Biedermann L, Mwinyi J, Scharl M, Frei P, Zeitz J, Kullak-Ublick GA, Vavricka SR, Fried M, Weber A, Humpf HU, Pescke S, Jetter A, Krammer G, Rogler G. Bilberry ingestion improves disease activity in mild to moderate ulcerative colitis - An open pilot study. J. Crohns colitis. 2013 May; 7(4)271-9. doi: 10.1016/j.crohns.2012.07.010. IF = 2.566 [Abstract]

Frei SM, Hemsley C, Pesch T, Lang S, Weber A, Jehle E, Rühl A, Fried M, Rogler G, Scharl M. The role for dickkopf-homolog-1 in the pathogenesis of Crohn's disease-associated fistulae. PLoS One. 2013 Nov 8;8(11):e78882.doi: 10.1371/journal.pone.0078882 IF = 3.73 [Abstract]http://www.ncbi.nlm.nih.gov/pubmed/22883440

Frei SM, Pesch T, Lang S, Weber A, Jehle E, Vavricka SR, Fried M, Rogler G, Scharl M. A Role for Tumor Necrosis Factor and Bacterial Antigens in the Pathogenesis of Crohn’s Disease–Associated Fistulae. Inflamm Bowel Dis. 2013 Dec; 19(13):2878-87.doi: 10.1097/01.MIB.0000435760.82705.23. IF = 5.119 [Abstract

Manser CN, Paul M, Rogler G, Held L, Frei T. Heat waves, incidence of infectious gastroenteritis, and relapse rates of inflammatory bowel disease: a retrospective controlled observational study. Am J Gastroenterol. 2013 Sep; 108 (9): 1480-5. Doi: 10.1038/ajg.2013.186. Epub 2013 Aug 13. IF = 7.553.[Abstract]

Nielsen OH, Bjerrum JT, Herfarth H, Rogler G. Recent advances using immunomodulators for inflammatory bowel disease. J Clin Pharmacol. 2013 Jun; 53(6): 575-88. Doi: 10.1002/jcph.2. Epub 2013 Feb 13. IF = 2.953 [Abstract]

Pittet V, Froehlich F, Maillard M, Mottet C, Gonvers JJ, Felley C, Vader JP, Burnand B, Michetti P, Schoepfer A and the EPACT-II update panelists. When do we dare to stop biological or immunomodulatory therapy for Crohn’s disease? Results of a multidisciplinary European expert panel. J. Crohns Colitis. 2013 April. In press, corrected proof. IF = 2.566 [Abstract]

Pittet V, Rogler G, Michetti P, Fournier N, Vader JP, Schoepfer AM, Mottet C, Burnand B, Froehlich F, for the SIBDC study group. Penetrating or Stricturing Diseases are the Major Determinants of Time to First and Repeat Resection Surgery in Crohn’s Disease. Digestion 2013, In press (DOI:10.1159/000350954). IF = 2.046 [Abstract]

Rogler D, Fournier N, Pittet V, Bühr P, Heyland K, Friedt M, Koller R, Rueger V, Herzog D, Nydegger A, Schäppi M, Schibli S, Spalinger J, Rogler G, Braegger C, Swiss IBD Cohort Study Group. Coping is excellent in Swiss children with inflammatory bowel disease: Results from the Swiss IBD cohort study. J. Crohn’s Colitis. 20132013 Nov 11. pii: S1873-9946(13)00355-3. IF = 3.385 [Abstract]

Rogler G. Inflammatory bowel disease cancer risk, detection and surveillance. Dig Dis. 2012; 30 Suppl 2:48-54. doi: 10.1159/000341893. Epub 2012 Nov 23. IF = 2.725 [Abstract]

Rogler G. Top-down or step-up treatment in Crohn’s desease? Dig Dis.2013;31(1): 83-90. doi: 10.1159/000347190. Epub 2013 Jun 17. IF = 2.26 [Abstract]

Rogler G, Vavricka S, Schoepfer A, Lakatos PL. Mucosal healing and deep remission: What does it mean? World J Gastroenterol. 2013 Nov 21;19(43): 7552-60.doi: 10.3748/wjg.v19.i43.7552. IF = 2.457 [Abstract]

Schaffer T, Flogerzi B, Schoepfer AM, Seibold F, Müller S. Increased titers of anti-Saccharomyces cerevisiae antibodies in Crohn’s disease patients with reduced H-ficolin levels but normal MASP-2 activity. J. Crohn’s colitis, Vol 7 (1), Feb 2013, e1-e10. IF = 3.385 [Abstract]

Scharl M, Rogler G. Inflammatory bowel disease: dysfunction of autophagy? Dig. Dis. 2012; 30 Suppl 3:12-9. doi: 10.1159/000342588. Epub 2013 Jan 3. IF = 2.725 [Abstract]

Scharl M, Vavricka SR, Rogler G. Review: New anti-cytokines for IBD: what is in the pipeline? Curr Drug Targets. 2013 Apr 25. [Epub ahead of print] IF = 3.553 [Abstract]

Schoepfer AM, Beglinger C, Straumann A, Safroneeva E, Romero Y, Armstrong D, Schmidt C, Trummler M, Pittet V, Vavricka SR. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm Bowel Dis. 2013 Feb; 19(2): 332-41. doi: 10.1097/MIB.0b013e3182810066. IF = 4.855 [Abstract]

Schoepfer AM, Dehlavi MA, Fournier N, Safroneeva E, Straumann A, Pittet V, Michetti P, Rogler G, Vavricka SR, Biroulet P. Diagnostic delay in Crohn’s Disease is associated with a complicated disease course and increased operation rate. American Journal of Gastroenterology. Am. J. Gastroenterol. 2013 Aug 27. Doi: 10.1038/ajg.2013.248. IF = 7.553 [Abstract]

Seibold F, Fournier N, Beglinger C, Mottet C, Pittet V, Rogler G; Swiss IBD cohort study group. Topical therapy is underused in patients with ulcerative colitis. J. Crohns Colitis. 2013 Apr 5. doi.pii: S1873-9946(13)00109 8. 10.1016/j.crohns.2013.03.005 [Epub ahead of print] IF = 2.566 [Abstract]

Siebert U, Wurm J, Gothe RM, Arvandi M, Vavricka SR, von Känel R, Begré S, Sulz MC, Meyenberger C, Sagmeister M; the Swiss IBD Cohort Study Group. Predictors of Temporary and Permanent Work Disability in Patients with Inflammatory Bowel Disease: Results of the Swiss Inflammatory Bowel Disease Cohort Study. Inflamm Bowel Dis. 2013 Mar; 19(4):847-855. IF = 4.855 [Abstract]

Spalinger MR, Lang S, Weber A, Frei P, Fried M, Rogler G, Scharl M. Loss of Protein Tyrosine Phosphatase Non-Receptor Type 22 Regulates Interferon-?-Induced Signaling in Human Monocytes. Gastroenterology. 2013 Feb 1. doi:pii: S0016-5085(13)00105-4. 10.1053/j.gastro.2013.01.048. [Epub ahead of print] IF = 11.675 [Abstract]

Spalinger MR, Lang S, Vavricka SR, Fried M, Rogler G, Scharl M. Protein Tyrosine Phosphatase Non-Receptor Type 22 modulates NOD2-induced cytokine release and autophagy. PLoS One. 2013 Aug 26; 8(8): e722384. Doi: 10.1371/journal.pone.0072384. IF = 3.73 [Abstract]

Sulz MC, Siebert U Arvandi M, Gothe RM, Wurm J, von Känel R, Vavricka SR, Meyenberger C, Sagmeister M. Predictors for hospitalization and outpatient visits in patients with inflammatory bowel disease. Results from the Swiss Inflammatroy Bowel Disease Cohort Study. European Journal of Gastroenterology & Hepatology. 2013. IF = 1.757 [Abstract]

Vavricka SR, Manser CN, Hediger S, Vögelin M, Scharl M, Biedermann L, Rogler S, Seibold F, Sanderink R, Attin T, Schoepfer A, Fried M, Rogler G, Frei P. Periodontitis and gingivitis in inflammatory bowel disease: a case-control study. Inflamm Bowel Dis. 2013 Dec;19(13):2768-77.doi: 10.1097/01.MIB.0000438356.84263.3b. IF = 5.119 [Abstract]

Vavricka SR, Rogler G. Intestinal absorption and vitamin levels: is a new focus needed? Dig Dis. 2012; 30 Suppl 3:73-80. doi: 10.1159/000342609. Epub 2013 Jan 3. IF =2.373 [Abstract]

Vavricka SR, Schoepfer AM, Safroneeva, E, Rogler G, Schwenkglenks, M, Achermann R. A shift from oral to intravenous iron supplementation therapy is observed over time in a large Swiss cohort of patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013 Mar-Apr; 19(4):840-6. doi: 10.1097/MIB.0b013e31827febbb. IF = 4.855 [Abstract]

Vavricka SR, Rogler G, Maetzler S, Misselwitz B, Safroneeva E, Frei P, Manser CN, Biedermann L, Fried M, Higgins P, Wojtal KA, Schoepfer AM. High altitude journeys and flights are associated with an increased risk of flares in inflammatory bowel disease patients. In press, corrected proof. J. Crohn’s colitis, available online 13 Aug 2013. IF = 3.385 [Abstract

Wojtal KA, Rogler G, Scharl M, Biedermann L, Frei P, Fried M, Weber A, Eloranta JJ, Kullak-Ublick GA, Vavricka SR. Fc gamma receptor CD64 modulates the inhibitory activity of infliximab. PLoS One. 2012;7(8):e43361. doi: 10.1371/journal.pone.0043361. Epub 2012 Aug 24. IF = 4.092 [Abstract]

Wojtal KA, Wolfram L, Frey-Wagner I, Lang S, Scharl M, Vavricka SR, Rogler G. The effects of vitamin A on cells of innate immunity in vitro. Toxicol in vitro. 2013 Apr 2; 27(5): 1525-1532. doi: 10. 1016/j.tiv.2013.03.013 [Epub ahead of print]. IF = 2.755 [Abstract]

2012

Becker HM, Bertschinger MM, Rogler G. Microparticles and their impact on intestinal immunity. Dig Dis. 2012;30 Suppl 3:47-54. doi: 10.1159/000342602. Epub 2013 Jan 3. IF = 2.373 [Abstract]

Biedermann L, Rogler G, Vavricka SR, Seibold F, Seirafi M, Treatments in Inflammatory Bowel Disease: Pregnancy and Breastfeeding in Inflammatory Bowel Disease. Digestion 2012; 86 (Suppl.1), 45-54. IF = 2.046. [Abstract]

Biedermann L, Rogler G. Environmental factors and their impact on the intestinal microbiota: a role for human disease?. Dig Dis. 2012;30 Suppl 3:20-7. doi: 10.1159/000342590. Epub 2013 Jan 3. IF = 2.373 [Abstract]

Burri E, Beglinger C, Lehmann FS, Treatments in Inflammatory Bowel Disease: Monitoring of Therapy for Inflammatory Bowel Disease. Digestion 2012; 86 (Suppl.1), 1-5. IF = 2.046. [Abstract]

Camara RJ, Juillerat P, Pittet V, Schoepfer AM, Begre S, von Känel R, the Swiss Inflammatory Bowel Disease Cohort Study G. Quality of life: a potentially useful measure to indicate subclinical flares in Crohn disease. Intern Med J l2012;42: e145-e151. IF= 1.541. [Abstract]

Chevaux JB, Vavricka SR, Rogler G, Lakatos PL, Schoepfer A, Peyrin-Biroulet L, Treatments in Inflammatory Bowel Disease: Mucosal Healing with Anti-TNF Antibodies. Digestion 2012; 86 (Suppl.1), 16-22. IF = 2.046. [Abstract]

Frei P, Biedermann L, Manser CN, Wilk M, Manz M, Vavricka SR, Rogler G, Treatments in Inflammatory Bowel Disease: Topical Therapies in Inflammatory Bowel Disease. Digestion 2012; 86 (Suppl.1), 36-44. IF = 2.046. [Abstract]

Girardin M, Manz M, Manser C, Biedermann L, Wanner R, Frei P, Safroneeva E, Mottet C, Rogler G, Schoepfer AM, Treatments in Inflammatory Bowel Disease: First-Line Therapies in Inflammatory Bowel Disease. Digestion 2012; 86 (Suppl.1): 6-10. IF = 2.046. [Abstract]

Herzog D, Landolt MA, Buehr P, Heyland K, Rogler D, Koller R, Rueger V, Pittet V, Nydegger A, Spalinger J, Schäppi M, Schibli S, Braegger CP, and the Swiss IBD Cohort Study Group, Low prevalence of behavioural and emotional problems among Swiss paediatric patients with inflammatory bowel disease. Arch Dis Child. Published online first 2012 Oct 19. IF = 1.318. [Abstract]

Lakatos PL, Lakatos L, Kiss LS, Peyrin-Biroulet L, Schoepfer A, Vavricka S, Treatments in Inflammatory Bowel Disease: Treatment of Extraintestinal Manifestations in Inflammatory Bowel Disease. Digestion 2012; 86 (Suppl.1), 28-35. IF = 2.046. [Abstract]

Manz M, Vavricka SR, Rogler G, Lakatos PL, Schoepfer A, Peyrin-Biroulet L, Treatments in Inflammatory Bowel Disease: Therapy of Steroid-Resistant Inflammatroy Bowel Disease. Digestion 2012; 86 (Suppl.1), 11-15. IF = 2.046 [Abstract]

Rogler G, Bernstein CN, Sood A, Goh KL, Yamamoto-Furusho JK, Abbas Z, Fried M. Role of biological therapy for inflammatory bowel disease in developing countries. Gut l2012;61: 706-12. IF= 10.111. [Abstract]

Rogler G, Vavricka S, Treatments in Inflammatory Bowel Disease, Preface. Digestion 2012; 86 (Suppl.1): IV. IF = 2.046. [Abstract]

Rogler G. Inflammatory bowel disease cancer risk, detection and surveillance. Dig Dis. 2012;30 Suppl 2:48-54. doi: 10.1159/000341893. Epub 2012 Nov 23. IF = 2.373 [Abstract]

Saurer L, Rihs S, Birrer M, Saxer-Seculic N, Radsak M, Mueller C, The Swiss IBDCS. Elevated levels of serum-soluble triggering receptor expressed on myeloid cells-1 in patients with IBD do not correlate with intestinal TREM-1 mRNA expression and endoscopic disease activity. J Crohns Colitis l 2012 Oct;6(9):913-23. Epub 2012 Mar 11. IF= 2.566. [Abstract]

Schaffer T, Flogerzi B, Schoepfer AM, Seibold F, Muller S. Increased titers of anti-Saccharomyces cerevisiae antibodies in Crohn's disease patients with reduced H-ficolin levels but normal MASP-2 activity. J Crohns Colitis l2012. IF= 2.566. [Abstract]

Scharl M, Frei S, Pesch T, Kellermeier S, Arikkat J, Frei P, Fried M, Weber A, Jehle E, Ruhl A, Rogler G. Interleukin-13 and transforming growth factor beta synergise in the pathogenesis of human intestinal fistulae. Gut l2012. IF= 10.111. [Abstract]

Scharl M, Mwinyi J, Fischbeck A, Leucht K, Eloranta JJ, Arikkat J, Pesch T, Kellermeier S, Mair A, Kullak-Ublick GA, Truninger K, Noreen F, Regula J, Gaj P, Pittet V, Mueller C, Hofmann C, Fried M, McCole DF, Rogler G. Crohn's disease-associated polymorphism within the PTPN2 gene affects muramyl-dipeptide-induced cytokine secretion and autophagy. Inflamm Bowel Dis l2012;18: 900-12. IF= 4.855. [Abstract]

Scharl M, Rogler G. The role for protein tyrosine phosphatase nonreceptor type 2 in regulating autophagosome formation. Ann N Y Acad Sci l2012;1257: 93-102. IF= 2.67. [Abstract]

Scharl M, Rogler G. Inflammatory bowel disease pathogenesis: what is new? Curr Opin Gastroenterol l2012;28: 301-9. IF= 4.33. [Abstract]

Scharl M, Wojtal KA, Becker HM, Fischbeck A, Frei P, Arikkat J, Pesch T, Kellermeier S, Boone DL, Weber A, Loessner MJ, Vavricka SR, Fried M, McCole DF, Rogler G. Protein tyrosine phosphatase nonreceptor type 2 regulates autophagosome formation in human intestinal cells. Inflamm Bowel Dis l2012;18: 1287-302.IF= 4.855. [Abstract]

Scharl M, Rogler G. Inflammatory bowel disease: dysfunction of autophagy?. Dig Dis. 2012;30 Suppl 3:12-9. doi: 10.1159/000342588. Epub 2013 Jan 3. IF = 2.373 [Abstract]

Schoepfer AM, Vavricka S, Zahnd-Straumann N, Straumann A, Beglinger C. Monitoring inflammatory bowel disease activity: clinical activity is judged to be more relevant than endoscopic severity or biomarkers. J Crohns Colitis l2012;6: 412-8. IF= 2.566. [Abstract]

Schoepfer AM, Safroneeva E, Vavricka SR, Peyrin-Biroulet L, Mottet C, Treatments in Inflammatory Bowel Disease: Treatment of Fibrostenotic and Fistulizing Crohn’s Disease. Digestion 2012; 86 (Suppl.1), 23-27. IF = 2.046. [Abstract]

Vavricka SR, Bentele N, Scharl M, Rogler G, Zeitz J, Frei P, Straumann A, Binek J, Schoepfer AM, Fried M, for the Swiss I, the Swiss IBDCSG. Systematic assessment of factors influencing preferences of crohn's disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL). Inflamm Bowel Dis l2012;18: 1523-1530. IF= 4.855. [Abstract]

Vavricka SR, Spigaglia SM, Rogler G, Pittet V, Michetti P, Felley C, Mottet C, Braegger CP, Rogler D, Straumann A, Bauerfeind P, Fried M, Schoepfer AM, Swiss IBDCSG. Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. Inflamm Bowel Dis March 2012; Vol. 18, Issue 3, pp. 496-505. IF= 4.855. [Abstract]

Vavricka SR, Rogler G. Intestinal absorption and vitamin levels: is a new focus needed?. Dig Dis. 2012;30 Suppl 3:73-80. doi: 10.1159/000342609. Epub 2013 Jan 3. [Abstract]

Wojtal KA, Rogler G, Scharl M, Biedermann L, Frei P, Fried M, Weber A, Eloranta JJ, Kullak-Ublick GA, Vavricka SR. Fc gamma receptor CD64 modulates the inhibitory activity of infliximab. PLoS One. 2012;7(8):e43361. doi: 10.1371/journal.pone.0043361. Epub 2012 Aug 24. IF = 4.092 [Abstract]

2011

Anderson CA, Boucher G, Lees CW, Franke A, D'Amato M, Taylor KD, Lee JC, Goyette P, Imielinski M, Latiano A, Lagace C, Scott R, Amininejad L, Bumpstead S, Baidoo L, Baldassano RN, Barclay M, Bayless TM, Brand S, Buning C, Colombel JF, Denson LA, De Vos M, Dubinsky M, Edwards C, Ellinghaus D, Fehrmann RS, Floyd JA, Florin T, Franchimont D, Franke L, Georges M, Glas J, Glazer NL, Guthery SL, Haritunians T, Hayward NK, Hugot JP, Jobin G, Laukens D, Lawrance I, Lemann M, Levine A, Libioulle C, Louis E, McGovern DP, Milla M, Montgomery GW, Morley KI, Mowat C, Ng A, Newman W, Ophoff RA, Papi L, Palmieri O, Peyrin-Biroulet L, Panes J, Phillips A, Prescott NJ, Proctor DD, Roberts R, Russell R, Rutgeerts P, Sanderson J, Sans M, Schumm P, Seibold F, Sharma Y, Simms LA, Seielstad M, Steinhart AH, Targan SR, van den Berg LH, Vatn M, Verspaget H, Walters T, Wijmenga C, Wilson DC, Westra HJ, Xavier RJ, Zhao ZZ, Ponsioen CY, Andersen V, Torkvist L, Gazouli M, Anagnou NP, Karlsen TH, Kupcinskas L, Sventoraityte J, Mansfield JC, Kugathasan S, Silverberg MS, Halfvarson J, Rotter JI, Mathew CG, Griffiths AM, Gearry R, Ahmad T, Brant SR, Chamaillard M, Satsangi J, Cho JH, Schreiber S, Daly MJ, Barrett JC, Parkes M, Annese V, Hakonarson H, Radford-Smith G, Duerr RH, Vermeire S, Weersma RK, Rioux JD. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet l2011;43: 246-52. IF= 34.284. [Abstract]

Biedermann L, Kerl K, Rogler G, Hofbauer GF. Drug-induced erythema nodosum after the administration of certolizumab in Crohn's disease. Inflamm Bowel Dis l2011. IF= 4.855. [Abstract]

Braegger CP, Ballabeni P, Rogler D, Vavricka SR, Friedt M, Pittet V, Swiss IBDCSG. Epidemiology of inflammatory bowel disease: Is there a shift towards onset at a younger age? J Pediatr Gastroenterol Nutr l2011;53: 141-4. IF= 2.298. [Abstract]

Cámara RJ, Gander ML, Begré S, von Känel R, Swiss Inflammatory Bowel Disease Cohort Study Group Post-traumatic stress in Crohn's disease and its association with disease activity. Frontline gastroenterology l2011;2: 2-9. IF=NA.

Cámara RJ, Begre S, von Kanel R, Swiss Inflammatory Bowel Disease Cohort Study G. Avoidance and inhibition do not predict nonrespondent bias among patients with inflammatory bowel disease. J Epidemiol l2011;21: 44-51. IF=6.414. [Abstract]

Cámara RJ, Lukas PS, Begre S, Pittet V, von Kanel R, Swiss Inflammatory Bowel Disease Cohort Study G. Effects of social support on the clinical course of Crohn's disease. Inflamm Bowel Dis l2011;17: 1277-86. IF= 4.855. [Abstract]

Cámara RJ, Schoepfer AM, Pittet V, Begre S, von Kanel R, Swiss Inflammatory Bowel Disease Cohort Study G. Mood and nonmood components of perceived stress and exacerbation of Crohn's disease. Inflamm Bowel Dis l2011;17: 2358-65. IF= 4.855. [Abstract]

Eloranta JJ, Wenger C, Mwinyi J, Hiller C, Gubler C, Vavricka SR, Fried M, Kullak-Ublick GA, Swiss IBDCSG. Association of a common vitamin D-binding protein polymorphism with inflammatory bowel disease. Pharmacogenet Genomics l2011;21: 559-64. IF= 3.865. [Abstract]

Fischbeck A and Leucht K, Frey-Wagner I, Bentz S, Pesch T, Kellermeier S, Krebs M, Fried M, Rogler G, Hausmann M and Humpf H-U (Co-last author). Sphingomyelin induces cathepsin D mediated apoptosis in intestinal epithelial cells and increases inflammation in DSS colitis. Gut. 2011 Jan;60(1):55-65. IF= 10.111. [Abstract]

Manz M, Michetti P, Seibold F, Rogler G, Beglinger C. Treatment algorithm for moderate to severe ulcerative colitis. Swiss Med Wkly l2011;141: w13235. IF= 1.895. [Abstract]

Olsen J, Bjerrum JT, Hansen M, Troelsen JT, Pittet V, Müller C, Rogler, G, Nielsen OH, Overexpression of receptors for insulin and epidermal growth factor in dysplastic inflamed correlates with increased cacer risk in patients with ulcerative colitis. Gastroenterology, Vol. 140, no. 5, pp. S-350-S-350, 2011. IF= 11.68.

Rivas MA, Beaudoin M, Gardet A, Stevens C, Sharma Y, Zhang CK, Boucher G, Ripke S, Ellinghaus D, Burtt N, Fennell T, Kirby A, Latiano A, Goyette P, Green T, Halfvarson J, Haritunians T, Korn JM, Kuruvilla F, Lagace C, Neale B, Lo KS, Schumm P, Torkvist L, National Institute of D, Digestive Kidney Diseases Inflammatory Bowel Disease Genetics C, United Kingdom Inflammatory Bowel Disease Genetics C, International Inflammatory Bowel Disease Genetics C, Dubinsky MC, Brant SR, Silverberg MS, Duerr RH, Altshuler D, Gabriel S, Lettre G, Franke A, D'Amato M, McGovern DP, Cho JH, Rioux JD, Xavier RJ, Daly MJ. Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. Nat Genet l2011;43: 1066-73. IF= 34.284. [Abstract]

Rogler G. 'Red alert' or not? - do we give our inflammatory bowel disease patients the right dietary recommendations? Digestion l2011;84: 236-7. IF= 2.046. [Abstract]

Rogler G. Interaction between susceptibility and environment: examples from the digestive tract. Dig Dis l2011;29: 136-43. IF= 2.373. [Abstract]

Rogler G. Pathogenesis of strictures in ulcerative colitis: a field to explore. Digestion l2011;84: 10-1. IF=2.046. [Abstract]

Scharl M, Frei P, Fried M, Rogler G, Vavricka SR. Association between Cogan's syndrome and inflammatory bowel disease: a case series. J Crohns Colitis l2011;5: 64-8. IF= 2.566. [Abstract]

Scharl M, Geisel S, Vavricka SR, Rogler G. Dying in yoghurt: the number of living bacteria in probiotic yoghurt decreases under exposure to room temperature. Digestion l2011;83: 13-7. IF= 2.046. [Abstract]

Scharl M, McCole DF, Weber A, Vavricka SR, Frei P, Kellermeier S, Pesch T, Fried M, Rogler G. Protein tyrosine phosphatase N2 regulates TNFalpha-induced signalling and cytokine secretion in human intestinal epithelial cells. Gut l2011;60: 189-97. IF= 10.111. [Abstract]

Scharl M, Weber A, Furst A, Farkas S, Jehle E, Pesch T, Kellermeier S, Fried M, Rogler G. Potential role for SNAIL family transcription factors in the etiology of Crohn's disease-associated fistulae. Inflamm Bowel Dis l2011;17: 1907-16. IF= 4.855. [Abstract]

Vavricka SR, Brun L, Ballabeni P, Pittet V, Prinz Vavricka BM, Zeitz J, Rogler G, Schoepfer AM. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol l2011;106: 110-9. IF= 7.282. [Abstract]

Vavricka SR, Schoepfer AM, Bansky G, Binek J, Felley C, Geyer M, Manz M, Rogler G, de Saussure P, Sauter B, Scharl M, Seibold F, Straumann A, Michetti P, Swiss I. Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey. Inflamm Bowel Dis l2011;17: 1530-9. IF= 4.855. [Abstract]

2010

Camara RJ, Begre S, von Kanel R. [The effect of stress-relieving interventions on inflammatory bowel disease: quality assessment of 10 therapeutic studies]. Z Psychosom Med Psychother l2010;56: 116-35. IF= 1.15. [Abstract]

Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, Lees CW, Balschun T, Lee J, Roberts R, Anderson CA, Bis JC, Bumpstead S, Ellinghaus D, Festen EM, Georges M, Green T, Haritunians T, Jostins L, Latiano A, Mathew CG, Montgomery GW, Prescott NJ, Raychaudhuri S, Rotter JI, Schumm P, Sharma Y, Simms LA, Taylor KD, Whiteman D, Wijmenga C, Baldassano RN, Barclay M, Bayless TM, Brand S, Buning C, Cohen A, Colombel JF, Cottone M, Stronati L, Denson T, De Vos M, D'Inca R, Dubinsky M, Edwards C, Florin T, Franchimont D, Gearry R, Glas J, Van Gossum A, Guthery SL, Halfvarson J, Verspaget HW, Hugot JP, Karban A, Laukens D, Lawrance I, Lemann M, Levine A, Libioulle C, Louis E, Mowat C, Newman W, Panes J, Phillips A, Proctor DD, Regueiro M, Russell R, Rutgeerts P, Sanderson J, Sans M, Seibold F, Steinhart AH, Stokkers PC, Torkvist L, Kullak-Ublick G, Wilson D, Walters T, Targan SR, Brant SR, Rioux JD, D'Amato M, Weersma RK, Kugathasan S, Griffiths AM, Mansfield JC, Vermeire S, Duerr RH, Silverberg MS, Satsangi J, Schreiber S, Cho JH, Annese V, Hakonarson H, Daly MJ, Parkes M. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet l2010;42: 1118-25. IF= 34.284. [Abstract]

Juillerat P, Pittet V, Vader JP, Burnand B, Gonvers JJ, de Saussure P, Mottet C, Seibold F, Rogler G, Sagmeister M, Felley C, Michetti P, Froehlich F, Swiss IBDCSG. Infliximab for Crohn's disease in the Swiss IBD Cohort Study: clinical management and appropriateness. Eur J Gastroenterol Hepatol l2010;22: 1352-7. IF= 1.598. [Abstract]

Muller S, Schaffer T, Flogerzi B, Seibold-Schmid B, Schnider J, Takahashi K, Darfeuille-Michaud A, Vazeille E, Schoepfer AM, Seibold F. Mannan-binding lectin deficiency results in unusual antibody production and excessive experimental colitis in response to mannose-expressing mild gut pathogens. Gut l2010;59: 1493-500. IF= 10.111. [Abstract]

Mwinyi J, Wenger C, Eloranta JJ, Kullak-Ublick GA. Glucocorticoid receptor gene haplotype structure and steroid therapy outcome in IBD patients. World J Gastroenterol l2010;16: 3888-96. IF= 2.471. [Abstract]

Nichita C, Stelle M, Vavricka S, El-Wafa Ali A, Ballabeni P, de Saussure P, Straumann A, Rogler G, Michetti P. Clinical experience with adalimumab in a multicenter Swiss cohort of patients with Crohn's disease. Digestion l2010;81: 78-85. IF= 2.046. [Abstract]

Pittet V, Juillerat P, Michetti P, Vader JP, Burnand B, Rogler G, Beglinger C, Seibold F, Mottet C, Felley C, Gonvers JJ, Froehlich F, Swiss IBDCSG. Appropriateness of therapy for fistulizing Crohn's disease: findings from a national inflammatory bowel disease cohort. Aliment Pharmacol Ther l2010;32: 1007-16. IF= 3.769. [Abstract]

Schmidt S, Guibal A, Meuwly JY, Michetti P, Felley C, Meuli R, Schnyder P, Denys A. Acute complications of Crohn's disease: comparison of multidetector-row computed tomographic enterography with magnetic resonance enterography. Digestion l2010;82: 229-38. IF= 2.046. [Abstract]

Schoepfer AM, Beglinger C, Straumann A, Trummler M, Vavricka SR, Bruegger LE, Seibold F. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol l2010;105: 162-9. IF= 7.282. [Abstract]

Schoepfer AM, Vavricka SR, Binek J, Felley C, Geyer M, Manz M, Rogler G, de Saussure P, Sauter B, Seibold F, Straumann A, Michetti P, Swiss I. Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: results of the FACTS survey. Inflamm Bowel Dis l2010;16: 933-8. IF= 4.855. [Abstract]

Vavricka SR, Rogler G. Recent advances in the etiology and treatment of Crohn's disease. Minerva Gastroenterol Dietol l2010;56: 203-11. IF=0.4. [Abstract]

Voegtlin M, Vavricka SR, Schoepfer AM, Straumann A, Voegtlin J, Rogler G, Ballabeni P, Pittet V, Buser A, Fried M, Beglinger C, Swiss IBDCS. Prevalence of anaemia in inflammatory bowel disease in Switzerland: a cross-sectional study in patients from private practices and university hospitals. J Crohns Colitis l2010;4: 642-8. IF= 2.566. [Abstract]
   
von Kanel R, Abbas CC, Begre S, Gander ML, Saner H, Schmid JP. Association between posttraumatic stress disorder following myocardial infarction and liver enzyme levels: a prospective study. Dig Dis Sci l2010;55: 2614-23. IF= 2.117. [Abstract]

2009

Binda E, Erhart D, Schenk M, Zufferey C, Renzulli P, Mueller C. Quantitative isolation of mouse and human intestinal intraepithelial lymphocytes by elutriation centrifugation. J Immunol Methods l2009;344: 26-34. IF=2.203. [Abstract]

Camara RJ, Ziegler R, Begre S, Schoepfer AM, von Kanel R, Swiss Inflammatory Bowel Disease Cohort Study g. The role of psychological stress in inflammatory bowel disease: quality assessment of methods of 18 prospective studies and suggestions for future research. Digestion l2009;80: 129-39. IF= 2.046. [Abstract]

Eloranta JJ, Zair ZM, Hiller C, Hausler S, Stieger B, Kullak-Ublick GA. Vitamin D3 and its nuclear receptor increase the expression and activity of the human proton-coupled folate transporter. Mol Pharmacol l2009;76: 1062-71. IF= 4.883. [Abstract]

Felley C, Vader JP, Juillerat P, Pittet V, O'Morain C, Panis Y, Vucelic B, Gonvers JJ, Mottet C, Froehlich F, Michetti P, the EIISG. Appropriate therapy for fistulizing and fibrostenotic Crohn's disease: Results of a multidisciplinary expert panel - EPACT II. J Crohns Colitis l2009;3: 250-256. IF= 2.566. [Abstract]

Juillerat P, Pittet V, Mottet C, Felley C, Gonvers JJ, Vader JP, Burnand B, Froehlich F, Wolters FL, Stockbrugger RW, Michetti P, Group E-I. Appropriateness of early management of newly diagnosed Crohn's disease in a European population-based cohort. Scand J Gastroenterol l2010;45: 1449-56. IF=2.019. [Abstract]

Juillerat P, Vader JP, Felley C, Pittet V, Gonvers JJ, Mottet C, Bemelman WA, Lemann M, Oresland T, Michetti P, Froehlich F, Group EIS. Appropriate maintenance treatment for Crohn's disease: Results of a multidisciplinary international expert panel - EPACT II. J Crohns Colitis l2009;3: 241-9. IF= 2.566. [Abstract]

Lee J, Tattoli I, Wojtal KA, Vavricka SR, Philpott DJ, Girardin SE. pH-dependent internalization of muramyl peptides from early endosomes enables Nod1 and Nod2 signaling. J Biol Chem l2009;284: 23818-29. IF= 4.773. [Abstact]

Manz M, Beglinger C, Vavricka SR. Fatal invasive pulmonary aspergillosis associated with adalimumab therapy. Gut l2009;58: 149. IF= 10.111. [Abstract]

Michetti P. Fistula treatment: the unresolved challenge. Dig Dis l2009;27: 387-93. IF= 2.373. [Abstract]
 
Michetti P, Stelle M, Juillerat P, Gassull M, Heil FJ, Stange E, Mottet C, Gonvers JJ, Pittet V, Vader JP, Froehlich F, Felley C, the EIISG. Appropriateness of therapy for active Crohn's disease: Results of a multidisciplinary international expert panel-EPACT II. J Crohns Colitis l2009;3: 232-240. IF= 2.566 [Abstract]

Mottet C, Vader JP, Felley C, Froehlich F, Gonvers JJ, Juillerat P, Stockbrugger R, Angelucci E, Seibold F, Michetti P, Pittet V, the EIISG. Appropriate management of special situations in Crohn's disease (upper gastro-intestinal; extra-intestinal manifestations; drug safety during pregnancy and breastfeeding): Results of a multidisciplinary international expert panel-EPACT II. J Crohns Colitis l2009;3: 257-263. IF= 2.566 [Abstract]

Muller S, Rihs S, Schneider JM, Paredes BE, Seibold I, Brunner T, Mueller C. Soluble TNF-alpha but not transmembrane TNF-alpha sensitizes T cells for enhanced activation-induced cell death. Eur J Immunol l2009;39: 3171-80. IF= 5.103. [Abstract]

Pittet V, Juillerat P, Mottet C, Felley C, Ballabeni P, Burnand B, Michetti P, Vader JP, Swiss IBDCSG. Cohort profile: the Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS). Int J Epidemiol l2009;38: 922-31.IF= 6.414. [Abstract]

Schoepfer AM, Beglinger C, Straumann A, Trummler M, Renzulli P, Seibold F. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis l2009;15: 1851-8. IF= 4.855. [Abstract]

Schoepfer AM, Flogerzi B, Seibold-Schmid B, Schaffer T, Kun JF, Pittet V, Mueller S, Seibold F. Low Mannan-binding lectin serum levels are associated with complicated Crohn's disease and reactivity to oligomannan (ASCA). Am J Gastroenterol l2009;104: 2508-16. IF= 7.282. [Abstract]

Schoepfer AM, Schaffer T, Mueller S, Flogerzi B, Vassella E, Seibold-Schmid B, Seibold F. Phenotypic associations of Crohn's disease with antibodies to flagellins A4-Fla2 and Fla-X, ASCA, p-ANCA, PAB, and NOD2 mutations in a Swiss Cohort. Inflamm Bowel Dis l2009;15: 1358-67. IF= 4.855. [Abstract]

Vavricka SR, Burri E, Beglinger C, Degen L, Manz M. Serum protein electrophoresis: an underused but very useful test. Digestion l2009;79: 203-10. IF=2.046. [Abstract]

Vavricka SR, Manz M, Burri E. Trichuris trichiura (whipworm). Clin Gastroenterol Hepatol l2009;7: A16. IF= 5.627. [Abstract]

Vavricka SR, Rogler G. Treatment of severe ulcerative colitis: differences in elderly patients? Dig Dis l2009;27: 315-21. IF= 2.373. [Abstract]

Vavricka SR, Rogler G. [Therapy of ulcerative colitis]. Praxis (Bern 1994) l2009;98: 209-12. IF=? [Abstract]

Vavricka SR, Rogler G. [Treatment of Crohn's disease]. Praxis (Bern 1994) l2009;98: 77-81.IF=? [Abstract]

Vavricka SR, Rogler G. New insights into the pathogenesis of Crohn's disease: are they relevant for therapeutic options? Swiss Med Wkly l2009;139: 527-34. IF= 1.895. [Abstract]

Wojtal KA, Eloranta JJ, Hruz P, Gutmann H, Drewe J, Staumann A, Beglinger C, Fried M, Kullak-Ublick GA, Vavricka SR. Changes in mRNA expression levels of solute carrier transporters in inflammatory bowel disease patients. Drug Metab Dispos l2009;37: 1871-7. IF= 3.716. [Abstract]

Zeitz J, Mullhaupt B, Fruehauf H, Rogler G, Vavricka SR. Hepatic failure due to hepatitis B reactivation in a patient with ulcerative colitis treated with prednisone. Hepatology l2009;50: 653-4. IF= 9.264. [Abstract]

2008

Juillerat P, Pittet V, Bulliard JL, Guessous I, Antonino AT, Mottet C, Felley C, Vader JP, Michetti P. Prevalence of Inflammatory Bowel Disease in the Canton of Vaud (Switzerland): A population-based cohort study. J Crohns Colitis l2008;2: 131-41. IF= 2.566. [Abstract]

Pittet V, Juillerat P, Mottet C, Felley C, Ballabeni, P, Burnand B, Michetti P, Vader JP and the Swiss IBD Cohort Study Group, Cohort Profile: The Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS), Int. J. Epidemiol. (2009) 38 (4): 922-931. IF = 6.414 [Abstract]

Schenk M, Mueller C. The mucosal immune system at the gastrointestinal barrier. Best Pract Res Clin Gastroenterol l2008;22: 391-409. IF=2.456. [Abstract]

2007

Carlson RM, Vavricka SR, Eloranta JJ, Musch MW, Arvans DL, Kles KA, Walsh-Reitz MM, Kullak-Ublick GA, Chang EB. fMLP induces Hsp27 expression, attenuates NF-kappaB activation, and confers intestinal epithelial cell protection. Am J Physiol Gastrointest Liver Physiol l2007;292: G1070-8. IF= 3.431. [Abstract]

Froehlich F, Juillerat P, Mottet C, Pittet V, Felley C, Vader JP, Gonvers JJ, Michetti P. Fibrostenotic Crohn's disease. Digestion l2007;76: 113-5. IF= 2.046. [Abstract]

Froehlich F, Juillerat P, Pittet V, Felley C, Mottet C, Vader JP, Michetti P, Gonvers JJ. Maintenance of surgically induced remission of Crohn's disease. Digestion l2007;76: 130-5. IF=2.046. [Abstract]

Gonvers JJ, Juillerat P, Mottet C, Pittet V, Felley C, Vader JP, Michetti P, Froehlich F. Maintenance of medically induced remission of Crohn's disease. Digestion l2007;76: 116-29. IF=2.046. [Abstract]

Guessous I, Juillerat P, Pittet V, Froehlich F, Burnand B, Mottet C, Felley C, Michetti P, Vader JP. Evaluating appropriateness of treatment for Crohn's disease: feasibility of an explicit approach. Digestion l2007;75: 46-52. IF=2.046. [Abstract]

Juillerat P, Christen-Zach S, Troillet FX, Gallot-Lavallee S, Pannizzon RG, Michetti P. Infliximab for the treatment of disseminated pyoderma gangrenosum associated with ulcerative colitis. Case report and literature review. Dermatology l2007;215: 245-51. IF=2.053. [Abstract]

Juillerat P, Froehlich F, Felley C, Pittet V, Mottet C, Gonvers JJ, Michetti P, Vader JP. EPACT II: project and methods. Digestion l2007;76: 84-91. IF= 2.046. [Abstract]

Juillerat P, Mottet C, Pittet V, Froehlich F, Felley C, Gonvers JJ, Vader JP, Michetti P. Extraintestinal manifestations of Crohn's disease. Digestion l2007;76: 141-8. IF= 2.046. [Abstract]

Juillerat P, Pittet V, Felley C, Mottet C, Froehlich F, Vader JP, Gonvers JJ, Michetti P. Drug safety in Crohn's disease therapy. Digestion l2007;76: 161-8. IF= 2.046. [Abstract]

Meier Y, Eloranta JJ, Darimont J, Ismair MG, Hiller C, Fried M, Kullak-Ublick GA, Vavricka SR. Regional distribution of solute carrier mRNA expression along the human intestinal tract. Drug Metab Dispos l2007;35: 590-4. IF=3.716. [Abstract]

Michetti P, Juillerat P, Mottet C, Pittet V, Gonvers JJ, Vader JP, Froehlich F, Felley C. Mild-to-moderate active luminal Crohn's disease. Digestion l2007;76: 92-8. IF= 2.046. [Abstract]

Michetti P, Mottet C, Juillerat P, Pittet V, Felley C, Vader JP, Gonvers JJ, Froehlich F. Severe and steroid-resistant Crohn's disease. Digestion l2007;76: 99-108. IF= 2.046. [Abstract]

Mottet C, Juillerat P, Pittet V, Gonvers JJ, Froehlich F, Vader JP, Michetti P, Felley C. Pregnancy and breastfeeding in patients with Crohn's disease. Digestion l2007;76: 149-60. IF= 2.046. [Abstract]

Mottet C, Juillerat P, Pittet V, Gonvers JJ, Michetti P, Vader JP, Felley C, Froehlich F. Upper gastrointestinal Crohn's disease. Digestion l2007;76: 136-40. IF= 2.046. [Abstract]

Schenk M, Bouchon A, Seibold F, Mueller C. TREM-1--expressing intestinal macrophages crucially amplify chronic inflammation in experimental colitis and inflammatory bowel diseases. J Clin Invest l2007;117: 3097-106. IF= 13.069. [Abstract]

Seibold F, Boldt AB, Seibold-Schmid B, Schoepfer AM, Flogerzi B, Muller S, Kun JF. Association of deficiency for mannan-binding lectin with anti-mannan antibodies in Crohn's disease: a family study. Inflamm Bowel Dis l2007;13: 1077-82. IF= 4.855. [Abstract]

Vavricka SR, Dirnhofer S, Degen L. Polyarteritis nodosa mimicking inflammatory bowel disease. Clin Gastroenterol Hepatol l2007;5: A22. IF= 5.627. [Abstract]

2006

Frei P, Fried M, Hungerbuhler V, Rammert C, Rousson V, Kullak-Ublick GA. Analysis of risk factors for low bone mineral density in inflammatory bowel disease. Digestion l2006;73: 40-6. IF=2.046 [Abstract]

Ismair MG, Vavricka SR, Kullak-Ublick GA, Fried M, Mengin-Lecreulx D, Girardin SE. hPepT1 selectively transports muramyl dipeptide but not Nod1-activating muramyl peptides. Can J Physiol Pharmacol l2006;84: 1313-9.  IF=1.849. [Abstract]

Vader JP, Froehlich F, Juillerat P, Burnand B, Felley C, Gonvers JJ, Mottet C, Pittet V, Dubois RW, Wietlisbach V, Michetti P. Appropriate treatment for Crohn's disease: methodology and summary results of a multidisciplinary international expert panel approach--EPACT. Digestion l2006;73: 237-48. IF=2.046. [Abstract]